SMITHS FALLS, ON, Feb. 10, 2015 /CNW/ - Tweed Marijuana Inc. (Tweed) and Canabo Medical Corporation (Canabo) are pleased to announce the launch of a collaborative research partnership on marijuana for medical purposes.
Canabo will conduct scientific and medical research through its network of healthcare practitioners at its medical clinics. This research data will be used to generate data to clarify the role of cannabis in various chronic conditions, including the management of chronic pain.
"Research data that is collected will be useful for a range of stakeholders including other clinicians, policy makers and to all industry involved in growing, selling, and marketing cannabis as a therapeutic modality," said Canabo CEO JC St-Amour. "Healthcare practitioners are seeking more information on how to practically incorporate cannabis into their practices, and accumulating a large-scale and reliable clinical dataset on the use of cannabinoids in clinical practice will be a major step forward in this endeavor. Partnering with Tweed and their customers on this research makes sense given their capability to provide a reliable supply of high quality medicine, and their reputation as a leader in customer care."
The scientific study will include establishing and implementing data management protocols and devising a systematic scientific methodology to capture consistent and complete study data. Research data will be conducted on real-world datasets, and patients who are enrolled in the scientific and medical research program (currently 1,100 patients, and projected to climb to over 15,000 patients) will have their data anonymously collected to be able to answer a range of research questions. The data is expected to provide a preliminary indication as to the effect of various cannabis strains on a range of chronic conditions. It will also contribute to clarifying specific dosages, modes of administration, and frequency for various conditions.
"Tweed's focus has been on research and medical education since the very beginning," said Bruce Linton, Chairman and Co-founder of Tweed. "We are proud to be the first partner in this exciting project and hope and expect to see further Licensed Producers become involved in this important work over the coming months."
The data acquired through this medical research will ensure that Tweed and future partners can continue to breed and grow the best medicine for patients, while building a knowledge base to help inform the dialogue with doctors about the place for medical cannabis within their practices.
About Canabo Medical Corporation
Canabo Medical Corporation is at the forefront of patient care in the field of prescription cannabinoids and medical marijuana. Its referral-only clinics incorporate evidence-based medicine in combination with expert opinion to provide a safe approach to treating the needs of patients suffering from chronic and disabling illnesses to improve their quality of life. The staff is dedicated to helping patients find effective treatment for chronic and serious conditions through the use of prescription cannabinoids and herbal cannabis, educating patients, physicians and the community and advancing research in the field of cannabinoids.
Tweed is Canada's first publicly traded medical marijuana company and the first geographically diversified producer with dual licenses under the Health Canada Marihuana for Medical Purposes Regulations.
Tweed provides an industry-leading selection of strains to customers who are seeking to treat their symptoms in a reliable, consistent way with a deep commitment and focus on customer care.
Notice regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Tweed Marijuana Inc. or Tweed Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include: (A) predictions of future demand; (B) plans to increase capital expenditure and construction related expenses; (C) anticipated production yields; (D) completion of construction and availability of new production rooms; and (E) forecasted available product selection. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability to obtain any necessary financing; the economy generally; the yield from Tweed's marijuana growing operations; consumer interest in products; competition; regulation and anticipated and unanticipated costs and delays. Although Tweed Marijuana Inc. has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The factors identified above are not intended to represent a complete list of the factors that could affect Tweed Marijuana Inc. or Tweed Inc. Additional factors are noted under "Part IV - Description of Risk Factors Associated with the Acquisition" in the Filing Statement of Tweed Marijuana Inc. dated as of June 30, 2014 and available at www.SEDAR.com. The forward-looking statements included in this news release are made as of the date of this news release and Tweed Marijuana Inc. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Tweed Marijuana Inc.
For further information: Jordan Sinclair, Media Relations Manager, Tweed, [email protected], 613-706-2185 ex 309; Canabo Medical Corporation, JC St-Amour, President and CEO, [email protected], 647-296-9871